An Analysis of the “Carry-over Effect” Following Successful Short-term Treatment of Transformed Migraine With Divalproex Sodium

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Download / Buy Article:



To determine whether successful short-term prophylactic treatment of transformed migraine may be followed by a continued respite from headaches once the treatment has been discontinued (“carry-over effect”).Background.–

The optimal duration of prophylactic treatment for pervasive headache and for migraine, in particular, is unknown.Methods.–

We prospectively evaluated a series of patients with transformed migraine, all of whom were managed according to a uniform treatment protocol involving prophylactic therapy with divalproex sodium for a period not exceeding 12 weeks. All patients reporting a positive treatment response were followed for at least 2 months after the discontinuation of divalproex sodium, and the incidence of the carry-over effect in that group was assessed.Results.–

A short-term carry-over effect occurred in 12 (60%) of 20 patients, but more sustained relief occurred in only 8 (40%).Conclusions.–

The successful short-term treatment of transformed migraine with divalproex sodium will often produce a short-term carry-over effect, but this response will be sustained only in a minority of patients.

Keywords: carry-over effect; divalproex sodium; migraine

Document Type: Research Article

Publication date: January 1, 2000

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more